US2019151308A1PendingUtilityA1

Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Assignee: OTSUKA PHARMA CO LTDPriority: Dec 27, 2002Filed: Jan 8, 2019Published: May 23, 2019
Est. expiryDec 27, 2022(expired)· nominal 20-yr term from priority
A61K 31/137A61K 31/4525A61K 31/381A61P 25/28A61K 31/165A61K 31/343A61K 31/496A61K 31/135A61P 25/18A61P 25/24A61K 31/138A61K 31/15A61K 31/382
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Claims

exact text as granted — not AI-modified
1 - 36 . (canceled) 
     
     
         37 . A pharmaceutical composition comprising at least one carbostyril derivative selected from the group consisting of DM-1458, DM-1454, and DCPP in combination with at least one serotonin reuptake inhibitor. 
     
     
         38 . The composition of  claim 37 , wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof. 
     
     
         39 . The composition of  claim 38 , wherein at least one serotonin reuptake inhibitor is citalopram. 
     
     
         40 . The composition of  claim 37 , further comprising at least one pharmaceutically acceptable carrier. 
     
     
         41 . The composition of any one of  claims 37  to  40  being useful for treatment of mood disorders. 
     
     
         42 . The composition of  claim 41  wherein the mood disorder is depression or major depressive disorder. 
     
     
         43 . The composition of  claim 42  wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms. 
     
     
         44 . The composition of any one of  claims 37  to  40  being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

Join the waitlist — get patent alerts

Track US2019151308A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.